| Jennifer L Rosquist, MD | |
|
4545 Cordata Pkwy Ste 1f, Bellingham, WA 98226-7264 | |
| (360) 752-5246 | |
| (360) 752-5679 |
| Full Name | Jennifer L Rosquist |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 4545 Cordata Pkwy Ste 1f, Bellingham, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235176264 | NPI | - | NPPES |
| 0229981 | Other | WA | L&I AND CRIME VICTIMS |
| 8455099 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 8402 (Montana) | Secondary |
| 208000000X | Pediatrics | MD00046745 (Washington) | Primary |
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309553 PECOS PAC ID: 9537073960 Enrollment ID: O20031118001062 |
News Archive
Between 70 and 100 percent of cancer patients receiving treatment suffer from fatigue related to their condition, according to the American Cancer Society, and up to one-half of all survivors have reported fatigue lasting months or even years after treatment. Fatigue can be one of the most distressing side effects of cancer treatment and can sometimes be overlooked by patients, caregivers and doctors.
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.
The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.
Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
› Verified 6 days ago
| Entity Name | Peacehealth Peace Island Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1487917233 PECOS PAC ID: 9335391044 Enrollment ID: O20121204000225 |
News Archive
Between 70 and 100 percent of cancer patients receiving treatment suffer from fatigue related to their condition, according to the American Cancer Society, and up to one-half of all survivors have reported fatigue lasting months or even years after treatment. Fatigue can be one of the most distressing side effects of cancer treatment and can sometimes be overlooked by patients, caregivers and doctors.
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.
The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.
Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
› Verified 6 days ago
| Entity Name | Peacehealth Peace Island Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508129842 PECOS PAC ID: 9335391044 Enrollment ID: O20130122000273 |
News Archive
Between 70 and 100 percent of cancer patients receiving treatment suffer from fatigue related to their condition, according to the American Cancer Society, and up to one-half of all survivors have reported fatigue lasting months or even years after treatment. Fatigue can be one of the most distressing side effects of cancer treatment and can sometimes be overlooked by patients, caregivers and doctors.
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.
The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.
Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer L Rosquist, MD 1115 Se 164th Ave Dept 358, Vancouver, WA 98683-8004 Ph: (360) 729-1412 | Jennifer L Rosquist, MD 4545 Cordata Pkwy Ste 1f, Bellingham, WA 98226-7264 Ph: (360) 752-5246 |
News Archive
Between 70 and 100 percent of cancer patients receiving treatment suffer from fatigue related to their condition, according to the American Cancer Society, and up to one-half of all survivors have reported fatigue lasting months or even years after treatment. Fatigue can be one of the most distressing side effects of cancer treatment and can sometimes be overlooked by patients, caregivers and doctors.
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.
The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.
Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
› Verified 6 days ago
Mara Wells Kelley, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4545 Cordata Pkwy, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5678 | |
Nancy K Bischoff, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 4545 Cordata Pkwy, Bellingham, WA 98226 Phone: 360-738-2200 | |
Steven F. Wallace, M.D.,PH.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 4545 Cordata Pkwy, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5679 | |
Julianne Elise Edwards, Pediatrics Medicare: Medicare Enrolled Practice Location: 2901 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-738-2200 Fax: 360-752-5683 | |
James J. Bochsler, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 4545 Cordata Pkwy, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-715-2486 | |
Scott W. Mcguinness, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 4545 Cordata Pkwy, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5678 |